Skip to main content
News Icon

News categories: Honors & Funding

New ImmunoSensation² research group

We introduce: Dr. Hannah Scheiblich

Hannah Scheiblich and her group are investigating the role of microglia during neuroinflammation and their role in neurodegenerative diseases. Situated at the Institute of Clinical Chemistry and Clinical Pharmacology of the University Hospital Bonn, Scheiblich recently started her research group at the cluster of excellence.

The central nervous system (CNS) is prone to inflammation both during normal aging and during the development and progression of neurodegenerative diseases. The observed inflammatory events are mainly mediated by microglia, the brain’s specific immune cells. Microglia are highly dynamic and responsive cells that promptly respond to homeostatic changes. These changes may switch the function of microglia from housekeepers to adaptive responders executing an inflammatory response that, if persistent, causes chronic neuroinflammation and neuronal damage.

Hannah Scheiblich and her group are investigating the role of microglia during neuroinflammation and their role in neurodegenerative diseases. By combining biochemistry, cell biology, and systems biology approaches, the group aims to understand the molecular and cellular mechanisms by which neuroinflammation affects immune cell function and the progression of neurodegenerative diseases. "One of the key objectives of our lab will be to unravel the fundamental principles of microglia-neuron interaction and its role in aging and disease" Scheiblich states. The group intends to develop novel experimental approaches to reveal the molecular mechanisms through which microglia control and consolidate neuronal survival to slow the progression of neurodegenerative processes. In addition, the group is also interested in studying how microglia may play a role in other neuronal disorders.


Short biography

Hannah Scheiblich recieved her PhD from the University of Veterenary Medicine Hannover in 2015. After a research stay at the at the Medical Research Council – Toxicology Unit, at teh University of Leicester, England, Scheiblich joined the department of Neurodegenerative Diseases and Gerontopsychiatry at the University Hospital Bonn, as a postdoctoral research fellow and joined the Institute of Innate Immunity at the University Hospital Bonn in 2022. From May 2023, Hanna Scheiblich is heading a Junior Research Group at the Institute of Clinical Chemistry and Clinical Pharmacology of the University Hospital Bonn.


Contact

Hannah Scheiblich

Institute of Clinical Chemistry and Clinical Pharmacology

University Hospital Bonn

Venusberg Campis 1

53127 Bonn

email: hannah.scheiblich@ukbonn.de

Hannah Scheiblich
© Hannah Scheiblich / UKB

Related news

Radosław P. Nowak is Professor of Immune Engineering and Drug Discovery at the University Hospital Bonn

News categories: Honors & Funding

Expert in the targeted degradation of proteins

Radosław P. Nowak is Professor of Immune Engineering and Drug Discovery at the University Hospital Bonn
View entry
Sandra Zeidler and Dr. Christine Wuebben (from left to right) from Bonn at the Pitch4Med Contest at the Heinrich Heine University Düsseldorf

News categories: Honors & Funding

ImmunoSensation entrepreneurs successfully pitch an innovative approach to fight respiratory viruses with an immunostimulatory nasal spray

A team of researchers in the group of Gunther Hartmann at the Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, and the Cluster of Excellence ImmunoSensation2 successfully pitched their start-up idea of Coldex, a nasal spray that provides protection from viral infections, at the Pitch4Med Contest at the Heinrich Heine University Düsseldorf and the 2nd Medical Pitch Contest of the Medical Faculty, University of Bonn.
View entry
Picture Florian Schmidt and Jan Hasenauer

News categories: Honors & Funding

Two ERC Consolidator Grants for ImmunoSensation members

Another big success for the University of Bonn in securing grants from the European Research Council (ERC), with three researchers receiving an ERC Consolidator Grant. Two of those grants go to ImmunoSensation2 researchers: Professor Jan Hasenauer of the LIMES Institute and Professor Florian I. Schmidt of the Institute for Innate Immunity.
View entry

Back to the news overview